MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
The following matters were submitted to a vote of shareholders at the Company’s Annual Meeting of Shareholders held on January 24, 2019:
(a) Votes regarding the election of eight directors:
|
Name |
For |
Withheld |
Broker Non-Votes |
|
James M. Anderson |
34,273,033 |
1,076,936 |
4,443,913 |
|
Dwight E. Ellingwood |
35,028,730 |
321,239 |
4,443,913 |
|
Jack Kenny |
34,752,181 |
597,788 |
4,443,913 |
|
John C. McIlwraith |
35,015,556 |
334,413 |
4,443,913 |
|
David C. Phillips |
34,201,968 |
1,148,001 |
4,443,913 |
|
John M. Rice, Jr. |
35,061,738 |
288,231 |
4,443,913 |
|
Catherine A. Sazdanoff |
34,602,998 |
746,971 |
4,443,913 |
|
Felicia Williams |
35,231,463 |
118,506 |
4,443,913 |
(b) Advisory votes regarding named executive officer compensation:
|
For |
Against |
Abstain |
Broker Non-Votes |
| 34,210,282 | 1,070,965 | 68,722 | 4,443,913 |
(c) Votes regarding the ratification of the Audit Committee’s appointment of Grant Thornton LLP as the Company’s Independent Registered Public Accountants for fiscal 2019:
|
For |
Against |
Abstain |
| 38,350,159 | 1,386,134 | 57,589 |
About MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO)
Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.